[1] Seo JA, Kim NH, Park SY, et al. Serum retinol-binding protein 4 levels are elevated in nonalcoholic fatty liver disease.Clin Endocrinol( Oxf),2008,68:555-560.
[2] Wu H, Jia W, Bao Y, et al.Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus . Diabetes Res Clin Pract, 2008, 79:185-190.
[3] Schina M, Koskinas J, Tiniakos D , et al.Circulating and liver tissue levels of retinol-binding protein4 in nonalcoholic fatty liver disease.Hepatol Res,2009,39:972-978.
[4] Nobili V, Alkhouri N, Alisi A,et al.Retinol-binding protein 4:a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Gastroenterol Hepatol,2009,7:575-579.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2018年更新版).实用肝脏病杂志,2018,21:177-186.
[6] Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean,obese,and diabetic subjects.N Engl J Med,2006,354: 2552-2563.
[7] Blaner WS.Vitamin A signaling and homeostasis in obesity, diabetes,and metabolic disorders.Pharmacol Ther,2019,197:153-178.
[8] Lee SA, Yuen JJ, Jiang H,et al.Adipocyte-specific over-expression of retinol-binding protein 4(RBP4) causes hepatic steatosis in mice.Hepatology,2016,64:1534-546.
[9] Zhong G, Kirkwood J, Won KJ, et al.Characterization of Vitamin A Metabolome in Human Livers With and Without Nonalcoholic Fatty Liver Disease.J Pharmacol Exp Ther, 2019,370:92-103.
[10] Wang X, Chen X, Zhang H, et al.Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease.Diabetes Metab,2019, S1262-3636:30069-30072.
[11] von Eynatten M, Humpert PM.Retinol-binding protein-4 in experimental and clinical metabolic disease.Expert Rev Mol Diagn,2008,8:289-299
[12] Yang Q, Graham TE, Mody N, et al.Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.Nature,2005,436:356-362.
[13] Kukla M, Ciupińska-Kajor M, Kajor M, et al.Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.Pol J Pathol,2010,61:147-153.
[14] Liu S, Wu HJ, Zhang ZQ, et al.The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol,2011,650:384-389.
[15] Zarzour RHA, Alshawsh MA, Asif M, et al. Adipocytokine regulation and antiangiogenic activity underlie the molecular mechanisms of therapeutic effects of phyllanthus niruriagainst non-alcoholic fatty liver disease. Nutrients,2018,10:1057.
[16] Tan Y, Sun LQ, Kamal MA, et al.Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. Biochim.Biophys.Acta Mol.Cell Boil.Lipids,2011,1811: 1045-1053. |
